Plain-English translation of NCT04278287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination treatment for esophageal squamous cell carcinoma—a type of esophageal cancer that cannot be surgically removed due to its size, location, or the patient's overall health. The treatment combines two chemotherapy drugs: and , given alongside radiation therapy. The study wants to see whether this medication combination can shrink tumors and prevent them from coming back within the first year.
Esophageal cancer that cannot be surgically removed is very difficult to treat and often has a poor outlook. This trial is testing whether this specific combination of chemotherapy drugs delivered with radiation therapy might be more effective than current treatment options, and whether paying special attention to patients' nutrition during treatment could help them tolerate and benefit from the therapy better.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first undergo a nutritional assessment to make sure the study can support your health during treatment. You will then receive chemotherapy infusions once a week for 5 to 6 weeks while undergoing radiation therapy at the same time. The study team will monitor your health closely, check your blood counts and organ function regularly, and track how well your tumor responds to treatment over the course of one year.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
China